| 1.54 0 (0%) | 04-04 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1.85 | 1-year : | 1.9 |
| Resists | First : | 1.58 | Second : | 1.62 |
| Pivot price | 1.55  |
|||
| Supports | First : | 1.51 | Second : | 1.26 |
| MAs | MA(5) : | 1.54 |
MA(20) : | 1.55  |
| MA(100) : | 1.25 |
MA(250) : | 1.94 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 9.9 |
D(3) : | 16.6 |
| RSI | RSI(14): 48.5 | |||
| 52-week | High : | 4.69 | Low : | 0.6 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ NGM ] has closed above bottom band by 26.0%. Bollinger Bands are 77.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 15 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.54 - 1.55 | 1.55 - 1.56 |
| Low: | 1.52 - 1.53 | 1.53 - 1.54 |
| Close: | 1.52 - 1.54 | 1.54 - 1.55 |
NGM Biopharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat liver and metabolic diseases, retinal diseases, and cancer. The company's product candidates include Aldafermin, an engineered analog of human hormone fibroblast growth factor 19, which is in Phase IIb clinical trials for the treatment of non-alcoholic steatohepatitis (NASH); and MK-3655, an agonistic antibody that activates fibroblast growth factor receptor 1c-beta-klotho, which is in Phase IIb clinical trials for use in the treatment of type 2 diabetes and NASH. Its products under development also comprise NGM120, an antagonist antibody that binds GFRAL that is in Phase I/II clinical trials; NGM621, an immunoglobulin 1 monoclonal antibody in Phase II clinical trials for the treatment of geographic atrophy; NGM707, an immunoglobulin-like transcript 2/ immunoglobulin-like transcript 4 dual antagonist monoclonal antibody that is in Phase I/II clinical trials for the treatment of patients with advanced solid tumors; and NGM831 and NGM438 for the treatment of advanced solid tumors. The company has research collaboration, product development, and license agreements with Merck Sharp & Dohme Corp.; and a collaboration agreement with Merck & Co., Inc. to focus primarily on the development of novel medicines for unmet patient needs in retinal and CVM diseases, including heart failure. NGM Biopharmaceuticals, Inc. was incorporated in 2007 and is headquartered in South San Francisco, California.
Wed, 24 Apr 2024
NGM Biopharma Investor Seeks Stock Appraisal In Del. - Law360
Fri, 05 Apr 2024
NGM Biopharmaceuticals' Strategic Merger and Corporate Transformation - TipRanks.com - TipRanks
Fri, 05 Apr 2024
NGM Bio Announces Closing of Tender Offer - GlobeNewswire
Tue, 19 Mar 2024
NGM Bio to Present Two Posters Highlighting Clinical Data from the Ongoing Phase 1/2 Clinical Trial of NGM707, a ... - Yahoo Finance
Wed, 13 Mar 2024
NGM BIOPHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti ... - Business Wire
Mon, 26 Feb 2024
NGM Biopharmaceuticals agrees to $135 million buyout By Investing.com - Investing.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 83 (M) |
| Held by Insiders | 2.889e+007 (%) |
| Held by Institutions | 21 (%) |
| Shares Short | 1,660 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.4433e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -17 % |
| Return on Assets (ttm) | 977.5 % |
| Return on Equity (ttm) | -38.5 % |
| Qtrly Rev. Growth | 4.42e+006 % |
| Gross Profit (p.s.) | -78.66 |
| Sales Per Share | -55.37 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -1.8 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -132 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.03 |
| Price to Cash Flow | 1.08 |
| Dividend | 0 |
| Forward Dividend | 1.68e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|